ACP
ABEO icon

Acuta Capital Partners’s Abeona Therapeutics ABEO Stock Holding History

Acuta Capital Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-4,454
Closed -$451K – 54
2015
Q3 		$451K Buy
+4,454
New +$591K 0.26% 53

Other funds holding ABEO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acuta Capital Partners's ABEO Position: Q4 2015 in Review

Acuta Capital Partners sold out of Abeona Therapeutics (ABEO) in Q4 2015, closing a stake of 4,454 shares — an estimated $451K sold.

Acuta Capital Partners first reported a position in ABEO in Q3 2015 and held it in 1 quarter. The position peaked at $451K in Q3 2015. 45 funds tracked by Wall St. Rank hold ABEO as of Q4 2015.

  • Acuta Capital Partners reported no remaining Abeona Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 4,454 Abeona Therapeutics shares in Q4 2015, an estimated $451K.
  • Acuta Capital Partners first reported a position in Abeona Therapeutics in Q3 2015 and held it in 1 quarter.
  • Acuta Capital Partners's Abeona Therapeutics position peaked at $451K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.